Experimental Evaluation of Perfluorocarbon Aerosol Generation with Two Novel Nebulizer Prototypes by Aramendia Iradi, Iñigo et al.
pharmaceutics
Article
Experimental Evaluation of Perfluorocarbon Aerosol
Generation with Two Novel Nebulizer Prototypes
Iñigo Aramendia 1 , Unai Fernandez-Gamiz 1,* , Alberto Lopez-Arraiza 2,
Carmen Rey-Santano 3, Victoria Mielgo 3, Francisco Jose Basterretxea 4, Javier Sancho 1 and
Miguel Angel Gomez-Solaetxe 2
1 Nuclear Engineering and Fluid Mechanics Department, University of the Basque Country UPV/EHU,
01006 Vitoria-Gasteiz, Araba, Spain; inigo.aramendia@ehu.eus (I.A.); javier.sancho@ehu.eus (J.S.)
2 Department of Nautical Science and Marine Systems, University of the Basque Country UPV/EHU,
48013 Portugalete, Bizkaia, Spain; alberto.lopeza@ehu.eus (A.L.-A.); miguel.solaetxe@ehu.eus (M.A.G.-S.)
3 Animal Research Unit, BioCruces Health Research Institute, 48903 Barakaldo, Bizkaia, Spain;
mariacarmen.reysantano@osakidetza.eus (C.R.-S.); victoriaeugenia.mielgoturuelo@osakidetza.eus (V.M.)
4 Department of Physical Chemistry, University of the Basque Country UPV/EHU, 48940 Leioa, Bizkaia,
Spain; franciscojose.basterretxea@ehu.eus
* Correspondence: unai.fernandez@ehu.eus; Tel.: +34-945-01-4066
Received: 19 November 2018; Accepted: 30 December 2018; Published: 5 January 2019


Abstract: The potential of non-invasive ventilation procedures and new minimally invasive
techniques has resulted in the research of alternative approaches as the aerosolization for the treatment
of respiratory distress syndrome (RDS). The aim of this work was to design two nebulizer prototypes
and to evaluate them studying the particle size distribution of the inhaled droplets generated with
distilled water and two perfluorocarbons (PFCs). Different experiments were performed with driving
pressures of 1–3 bar for each compound. An Aerodynamic Particle Sizer was used to measure the
aerodynamic diameter (Da), the mass median aerodynamic diameter (MMAD) and the geometric
standard deviation (GSD). The results showed that both prototypes produced heterodisperse aerosols
with Da mean values in all cases below 5 µm. The initial experiments with distilled water showed
MMAD values lower than 9 µm and up to 15 µm with prototype 1 and prototype 2, respectively.
Regarding the PFCs, relatively uniform MMAD values close to 12 µm were achieved. The air delivery
with outer lumens of prototype 1 presented more suitable mass distribution for the generation and
delivery of a uniform aerosol than the two half-circular ring geometry proposed in the prototype 2.
Keywords: drug delivery; nebulizer; aerosol; aerodynamic particle sizer; particle size distribution
1. Introduction
Respiratory distress syndrome (RDS), which results from a lack of pulmonary surfactant, remains
as the main cause of mortality and morbidity in preterm infants [1]. The major components of
surfactant are lipids which are responsible for adjusting the surface tension during the breathing cycle,
as described by Nkadi et al. [2]. Parra et al. [3] made a detailed review of the composition, structure
and properties of the surfactant and problems due to its inactivation. The current clinical surfactant
replacement therapy involves endotracheal intubation and the application of mechanical ventilation,
which are techniques that may lead to lung injury (Jobe et al. [4]). Therefore, clinicians are constantly
looking for new soft approaches in order to minimize the invasive intervention (Herting et al. [5]).
Non-invasive ventilation procedures, such as continuous positive airway pressure (CPAP), along with
new minimally invasive surfactant therapy (MIST) techniques have emerged as alternatives for
the treatment of RDS [6,7]. They can be classified into four main groups: pharyngeal surfactant
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instillation, administration via a laryngeal mask, surfactant instillation via a thin catheter and surfactant
aerosolization [8]. More et al. [9] carried out a meta-narrative review of the studies using these types
of techniques comparing the safety and feasibility between them.
Verder et al. [10] introduced in 1994 the INSURE (INtubation SURfactant Extubation) technique,
which consists of intubating the preterm infant for surfactant administration with quick extubation
to nCPAP (nasal Continuous Positive Airways Pressure). Dani et al. [11] confirmed that INSURE
procedure is a safe and feasible method to be applied in preterm infants with a high percentage of
success. Recently, Aguar et al. [12] reported that MIST was as effective as INSURE in avoiding the
need for further mechanical ventilation.
According to Dolovich et al. [13], aerosol drug delivery devices can be classified in three
different types: pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPI) and nebulizers.
Rubin et al. [14] described the aerosol therapy with each one of these devices and the major mechanisms
of aerosol deposition. Nebulizers convert a liquid in solution or suspension into small droplets.
They are widely used for hospital emergency care and pediatric patients, as they do not require
specialized inhalation maneuvers apart from the patient’s spontaneous breathing. Therefore, in contrast
to pMDIs or DPIs, they can be used for patients who are unable to control their breathing or consciously
follow instructions, as preterm infants affected with RDS [15]. O’Callaghan and Barry [16] analyzed
the nebulizers operation principle and described some of the most important parameters to define
an aerosol as well as some methods to measure particle size, aerosol deposition and nebulizer
output. Nebulizers are classified by the type of energy used for the disintegration of the liquid.
Pressure nebulizers convert liquid pressure into kinetic energy that causes the liquid to break into
droplets. There are two types of pressure nebulizers, jet nebulizers and swirl nebulizers. Jet nebulizers
are based on the Bernoulli principle, where a pressurized flow of gas, generally air, is directed through
a constricted orifice where the velocity of the airflow is increased to create a jet stream. This jet
stream creates a sub-atmospheric pressure zone (vacuum) which draws the fluid up the capillary
tube. The impact of a jet stream with the liquid and the extreme difference in velocity between them
produces the aerosol particles or droplets [15,17]. Swirl nebulizers cause the liquid to spin as it exits the
nozzle, forming a hollow cone that facilitates the breakup of the liquid. Another type is the pneumatic
nebulizer, which uses the energy from compressed air to break up a liquid stream. Ultrasonic nebulizers
remove the need for a compressed air source and, instead, a high-frequency vibration generated by
a piezoelectric crystal is used to the formation of droplets. However, this option was dismissed due
to the significant heating of the nebulizer solution and difficulties with nebulizing high-viscosity
liquids as the pulmonary surfactant [13]. Vibrating mesh nebulizers force liquid medications through
multiple apertures in a mesh to generate aerosol but they still present some challenges. For instance,
viscous drugs can clog the pores, cleaning the mesh can be difficult and they are more expensive
than the other alternatives, as explained by Pillow et al. [18]. Tiemersma et al. [19] evaluated lung
deposition of salbutamol using two vibrating mesh nebulizers, designed specifically for use in preterm
infants, and they compared them with a jet nebulizer and a pMDI. The results showed that lung
deposition was significantly higher for the investigational vibrating mesh nebulizers in an in vitro
model of a preterm infant of 32-weeks gestational age. Recently, Choi et al. [20] manufactured a
micro-porous mesh nebulizer with an optimized Pd-Ni membrane filter. Their results showed a good
biocompatibility and an excellent durability which makes this nebulizer quite promising for its use in
biomedical engineering.
Mazela et al. [21] reported the dilemma with regard to aerosol delivery to preterm infants.
This study described the low pulmonary deposition (0.5–1% of the nominal dose) in neonates with
either jet nebulizers or pressurized metered-dose inhalers (pMDIs) and how different factors can
alter the aerosol delivery in the ventilated infant. Kohler et al. [22] studied the lung deposition in
seventeen spontaneously breathing preterm infants with three different nebulizers. They confirmed
that, on average, not more than 1% of the nominal dose reached the lungs with the jet and ultrasonic
nebulizers employed. Danaei et al. [23] made a review of the impact of particle size on drug
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delivery in different clinical applications. To date, five clinical studies have been carried out with
aerosolized surfactant administration [24–28], showing some discrepancies in the results. The most
recent study of Minocchieri et al. [28] suggests minimal adverse effects within the first week of
life after nebulization treatment and longer time to reach CPAP failure criteria compared with the
control group. Special catheters have been used for the administration of intracorporeal nebulized
surfactant. Rey-Santano et al. [29] showed that surfactant delivered as an aerosol, by means of an
inhalation catheter, can produce a similar response to rapid intratracheal bolus instillation of the
same dose, in terms of gas exchange and pulmonary mechanics, and resulting in less lung damage.
Additionally to surfactant, the use of perfluorocarbons (PFCs) has been studied to improve lung
function. Murgia et al. [30,31] carried out in vitro studies with three intratracheal inhalation catheters
to deliver an aerosol of PFC and surfactant, showing their feasibility for treating the RDS and how
ventilation strategies influence in their efficiency. Burkhardt et al. [32] studied the behavior of a
PFC-surfactant mixture (Persurf) in depleted rats and observed an improvement in oxygenation as well
as a more homogenous distribution compared with the surfactant alone. Goikoetxea et al. [33] reported
an enhancement in deposition delivering an intracorporeal aerosol beyond the third generation of
neonatal branching by means of an inhalation catheter. Additionally, they studied by a numerical
modeling the surfactant aerosol properties within a neonatal physical model and validated the results
with experimental data [34]. Syedain et al. [35] developed a novel aerosol generator for surfactant
aerosol delivery in preterm infants. Even though this device still requires the intubation of the neonate
it showed promising results, with the generation of small aerosol droplets and operating with low
airflow. Milesi et al. [36] developed a new atomizing device, consisting of a small multilumen catheter,
for intracorporeal nebulization of surfactant during CPAP. In a recent research, they conducted a study
to deliver nebulized surfactant without the need of intubation in spontaneously breathing preterm
lambs, showing encouraging results [37]. Computational Fluid Dynamics (CFD) tools have also shown
great potential to analyze the effects of pharmaceutical aerosols in airway models, as shown in the
study of Xi et al. [38]. Aramendia et al. [39] developed a numerical model with CFD techniques to
study the particle size and cumulative mass distribution of two different PFC compounds.
Nebulization can be a useful alternative to tracheal instillation for the treatment of RDS, since it
can produce a similar response in terms of gas exchange and pulmonary mechanics [29]. However,
discrepancies in the experimental and clinical results have been found [24–28] that can be attributed to
several factors, such as the use of different animal models of lung injury or the use of different types of
aerosol devices. Therefore, the current research has been performed to study the influence in the particle
size distribution of two prototypes with different distal shapes. The aim is to evaluate the feasibility
to generate droplets with potential to be delivered in the supraglottic region. We hypothesized that
with these nebulizers a PFC aerosol could be generated with particles within the respirable size.
To that end, (1) two novel nebulizer prototypes have been designed and manufactured, (2) the particle
size distribution with distilled water and two PFCs has been measured with each one, and (3) their
performance was analyzed and compared with the results obtained in previous research.
2. Materials and Methods
Additive manufacturing techniques, by means of the 3D SYSTEMS-ProJet MJP 5600 printer, were
employed for the manufacturing of the prototypes tested in the current study. The Polyjet technology
was used, based on the photopolymerization of resin, which consists in the projection of micro droplets
over a platform along with an emission of ultraviolet light which solidifies the material with a curing
procedure. One of the most indispensable characteristics for the manufacturing of these nebulizers is
the generation of the wax support, which is removed with heat after the printing. This technology has
a height layer precision of 16 µm, allowing the manufacturing of the holes required in these prototypes
between 0.3–0.7 mm. The material used is translucent clear ultraviolet curable plastic with a solid
density of 1.18 g/cm3.
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Few works have studied drug delivery devices for neonates. The design of these prototypes
has been carefully carried out after analyzing previous research with different types of inhalation
catheters and nebulizers for preterm infant population. For instance, Rey-Santano et al. [29] showed
improvements in lung function with aerosol delivery to the same extent than tracheal instillation.
Syedain et al. [35] evaluated an intrapulmonary aerosol generation device for surfactant delivery
in preterm infants. Holbrook et al. [40] developed several nebulization devices to administer
pharmaceutical aerosols to ventilated infants. However, these devices require the intubation of the infant.
Goikoetxea et al. [33] studied the performance of an inhalation catheter (Aeroprobe, Trudell Medical
International) to deliver surfactant and PFC beyond the third generation of the neonatal airways.
Recently, Milesi et al. [36,37] developed a nebulizer to deliver relatively large particles in the subglottic
and supraglottic region.
For the aforementioned, further research is needed to develop a device intended for neonates in
order to optimize the drug delivery in a noninvasive and effective way. Both prototypes designed
and presented in the current manuscript are classified within twin-fluid nebulizers with external
mixing, that is the gas interacts with the liquid outside of the nebulizer. Twin-fluid nebulizers typically
produce a full cylindrical spray cone with relatively small droplets at high liquid mass flow rates [41].
Two different prototypes have been developed that allow aerosol generation, offering potential to
drug delivery without the need of intubation. Figure 1a shows a 3D visualization of the prototypes.
Prototype 1 consists of six small outer lumens, where compressed air is delivered, and a central lumen
where the liquid flows; see Figure 1b. On the other hand, in the prototype 2, the outer lumens have
been replaced with two half-circular rings; see Figure 1c. The central lumen has the same dimensions
in both prototypes and the area of the two half-circular rings in the prototype 2 is equal to the area
of the six outer lumens of the prototype 1. Figure 1d,e show the distal section of the manufactured
nebulizers, prototype 1 and prototype 2 respectively. Figure S1 in supplementary information provides
a picture of the manufactured nebulizer prototype 2.
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Three compounds have been used in order to analyze and compare the operation of the
two prototypes presented in the current study, distilled water (H2Od) and two different PFCs,
perfluorodecalin (PFD; C10F18, F2 Chemicals Ltd., Lancashire, UK) and FC75 (C8F16O, Fluorinert,
3M, Neuss, Germany). Their properties can be seen in Table 1. Distilled water is used for drug dilution
and the aerosolization of aqueous medications whereas the biophysical properties of PFCs have shown
to improve oxygenation and to reduce lung injury in cases of severe respiratory insufficiency, as studied
by Guo et al. [42]. Partial liquid ventilation with PFCs has been used in the experimental field and
proven effective in the treatment of various lung diseases in a wide range of animal models, reaching
human clinical trials [43]. The aerosol delivery of PFCs has been suggested as a promising method
over instillation to improve lung function [44]. Von der Hardt et al. [45] compared different PFCs in
surfactant-depleted rabbits showing their effectiveness and suitability for aerosol treatment.
Table 1. Properties of H2Od and perfluorocarbons (PFCs).
Parameter H2Od PFD FC75
Density ($) [g/mL] 0.99 1.95 1.78
Kinematic viscosity (ν) [cSt] 1.003 2.70 0.81
Surface tension (γ) [dyn/cm] 73 15 15
An Aerodynamic Particle Sizer (APS) spectrometer was used to measure the aerosol produced
with both nebulizer prototypes. The aerosol drawn into the inlet is immediately split into a sample
flow, through the inner nozzle, and a sheath flow, through the outer nozzle. This device, based on a
double-crested optical system for unmatched sizing accuracy, generates a signal every time a particle
crosses two laser beams placed within the inlet nozzle, providing high resolution measurements for
droplets between 0.5 and 20 µm (see Figure 2). The acceleration of droplets, due to inertia, is smaller for
larger droplets. Therefore, the APS theory operation to calculate this acceleration is based on the time
between the peaks of the signal produced by the two laser beams, also known as time of flight. Then,
the APS memory, which is initially calibrated, converts each time of flight measurement recorded to the
corresponding aerodynamic particle diameter, described as the diameter of a spherical particle with a
density of a water droplet (1000 kg/m3) that has the same settling velocity as the measured particle.
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Fig re 2. (a) Aerodynamic Particle Sizer (APS) operation scheme, (b) detail view with aerosol droplets
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i s t e i t t ti l i i t i t
r sols generated with both nebulizer prototypes. The mass median aerodynamic iameter (MMAD),
the mean aerodynamic diameter (Da) and the geome ric standard deviation (GSD) were analyz d.
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The central inlet of the prototypes, where the liquid is delivered, was connected to a three-way stopcock
to control the charge of the compound into the liquid chamber. Then, an air pressure controller was
used to provide compressed air to both the small piston placed within the liquid chamber and to the
side connection of the nebulizer prototype, where the air is delivered to the outer lumens and to the
two half-circular rings respectively. The air was supplied by an air cylinder shoulder with purity higher
than 99.999% assuring that the air delivered is empty of impurities that could block the nebulizer
prototypes lumens or the APS nozzles. The distance between the inlet nozzle of the APS and the distal
section of the nebulizer prototypes was controlled during the experiments in order to get a value
as close as possible to the average particle concentration recommended by the device guidelines of
1000 droplets/cm3. The measurements recorded by the APS are classified in four categories according
to their aerodynamic diameter value. In the first category, those droplets with a diameter smaller
than 0.5 µm, in the second one the droplets that are within the spectrometer measuring range from
0.5 µm to 20 µm, in the third category the droplets that cross the laser beams at the same time and
cannot be sized, and in the last category those droplets larger than the measuring range of 20 µm. Thus,
it was important to check that in every sample taken most of the droplets were classified in the second
category, which comprises the droplets within the measuring range of the APS. All the samples were
recorded, stored and analyzed by the Aerosol Instrument Manager software associated with the APS.
Figure 3b provides an example of the aerosol visualization obtained with prototype 1. Additionally,
in Figure S2 of supplementary information an aerosolization example with prototype 2 can be found.
Figures S3 and S4 show the experimental setup placed in the laboratory for the nebulization with
both prototypes.
Pharmaceuticals 2019, 11, 19 6 of 13 
 
analyzed. The central inlet of the prototypes, where the liquid is delivered, was connected to a 
three-way stopcock to control the c a ge of the compound into the liquid chamber. Then, an air 
pressure controller was us d to rovi e compressed air to both t  small piston placed within the 
liqui  chamber and to the side connection of the nebulizer prototype, where the air is delivered o 
the outer lume s and to the two half-circular rings respectively. The air was suppli d by an air 
cylinder sho lde  with puri y higher than 99.999% assuri g that th  air delivered is empty of 
impurities that co ld block the nebuliz  prototy es lumens or the APS nozzles. T  distanc  
between the inlet nozzle of the APS and t  i t l s ction of the nebulizer proto ypes was controlled 
during the experiments in order to get a value as close as possibl  o the average p rticle 
con entration recommended by the device guidelines of 1000 droplets/cm3. The measur ments 
recorded by he APS ar  classified in four ategories according to the r aerodynamic diameter value. 
In the first category, those droplets with a diameter smaller than 0.5 µm, in the second one th  
droplets that are within the spectrometer me su ing range from 0.5 µm to 20 µm, in the third 
category the droplets t a  cross th  laser b ams at the s me time and cannot be sized, and in the l st 
category thos  droplets larger than the measuring range of 20 µm. Thus, it was important to check 
that in every sample ta en most of the droplets were classified in the s cond category, which 
comprises the droplets within the measuring range of the APS. All t  samples were recorded, 
stored and analyzed by the Aerosol Instrument Manager software associ t d with he APS. Figure 
3b provides an exampl  of th  aerosol visualization obtained with prototype 1. Additionally, in 
Figure S2 of supplem ntary information a  aeros lization example with prot ype 2 can be found. 
Figures S3-S4 show t e exp rimental setup placed in the laboratory for the nebulization with both 
pr otypes. 
 
 
(a) (b) 
Figure 3. (a) Experimental setup used for the particle size characterization and (b) an aerosol 
visualization of a nebulizer prototype. 
Statistics 
A statistical analysis was carried out with the data obtained. The measurements were repeated 
five times for each compound and prototype and the mean ± standard deviation were calculated for 
Da, MMAD and GSD. A one-way analysis of variance (ANOVA) was performed to identify any 
statistically significant differences between the prototypes and each compound for aerosolization 
rates with a p < 0.05 accepted as significant. 
3. Results 
In the present study, the characterization of the aerosol was studied by means of the MMAD, 
Da and GSD. The MMAD measures the aerodynamic diameter at which 50% of the aerosol mass is 
present in droplets below this value. The aerosols produced by prototype 1, during distilled water 
Figure 3. (a) Experimental setup used for the particle size characterization and (b) an aerosol
visualization of a nebulizer prototype.
Statistics
A statistical analysis was carried out with the data obtained. The measurements were repeated
five times for each compound and prototype and the me n ± standard deviation were calculated
for Da, MMAD and GSD. A one-way analysis of variance (ANOVA) was performed to iden ify any
statistically significant differ nces between the prototypes and each compound for aerosoliza on rates
with a p < 0.05 accepte as significan .
3. Results
In the present study, the characterization of the aerosol was studied by means of the MMAD,
Da and GSD. The MMAD measures the aerodynamic diameter at which 50% of the aerosol mass is
present in droplets below this value. The aerosols produced by prototype 1, during distilled water
Pharmaceutics 2019, 11, 19 7 of 13
aerosolization, provided MMAD values lower than 9 µm. Specifically, a minimum value was observed
with a driving pressure of 1 bar (5.96± 0.76 µm) and a maximum value with a driving pressure of 2 bar
(8.80 ± 1.84 µm), see Figure 4a. On the contrary, larger MMAD measurements were achieved during
aerosolization with prototype 2 with values up to 15 µm. A minimum value with a driving pressure of
1 bar (13.03 ± 2.62 µm) and a maximum peak with a driving pressure of 2 bar (14.93 ± 1.13 µm) were
obtained. It should be noted that for both prototypes the minimum and maximum MMAD values
were obtained for the same driving pressures, 1 and 2 bar respectively.
The aerodynamic diameter is described as the diameter of a spherical particle with a density of a
water droplet (1000 kg/m3) that has the same settling velocity as the particle. The results obtained
with prototype 1 and distilled water maintained a stable value regardless of the driving pressure,
between 3.32 ± 0.20 µm (1 bar) and 3.40 ± 0.31 µm (1.5 bar). Prototype 2, however, presented a
smooth increment in the aerodynamic diameter proportionally with the driving pressure, as shown in
Figure 4b.
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The GSD is a dimensionless number which provides an indication of the spread of sizes of 
droplets that form the aerosol. An aerosol with a GSD value below 1.2 indicates that the aerosol is 
formed by droplets with the same or very nearly size (monodisperse aerosol), whereas a value above 
1.2 shows that the aerosol contains droplets of many different sizes (heterodisperse aerosol), as 
defined by O’Callaghan et al. [16]. Both prototypes produced heterodisperse aerosols, as showed in 
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P (bar) 
PROTOTYPE 1 (a) PROTOTYPE 2 (a) 
1 1.79 ± 0.03 1.95 ± 0.31 
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(a) Values are given as mean ± standard deviation. 
After the preliminary tests carried out with distilled water, PFCs were tested in order to study 
more in detail the behavior of both prototypes under a compound that can be used subsequently as a 
mixture with surfactant. With regard to the MMAD values, the results with both prototypes showed 
relatively uniform values, close to 12 µm, for the two driving pressures considered. The largest value 
Figure 4. (a) MMAD (µm) and (b) Da (µm) values for prototype 1 (P1) and prototype 2 (P2) as a function
of the driving pressure for distilled water (H2Od). Values are given as mean ± standard deviation.
The GSD is a dimensionless number which provides an indication of the spread of sizes of droplets
that form the aerosol. A aerosol with a GSD value below 1.2 i icates that the aerosol is formed
by droplets with the s me or very nearly size (monodisperse aerosol), wherea a valu bove 1.2
shows that the a rosol contains dr plets of many different sizes (h terodisperse aero ol), as defined
by O’Callag n et al. [16]. Both prototypes produced heterodisperse aerosols, as showed in Table 2,
with GSD values between 1.79 ± 0.03 (prot ype 1 at 1 bar) and 2.47 ± 0.28 (prototype 2 at 2 bar).
Table 2. Geometric standard deviation (GSD) for both prototypes nebulizing H2Od at different pressures.
P (bar) PROTOTYPE 1 (a) PROTOTYPE 2 (a)
1 1.79 ± 0.03 1.95 ± 0.31
1.5 1.86 ± 0.05 2.31 ± 0.26
2 1.86 ± 0.06 2.47 ± 0.28
3 1.90 ± 0.05 2.37 ± 0.12
(a) Values are given as mean ± standard deviation.
After the preliminary tests carried out with distilled water, PFCs were tested in order to study
more in detail the behavior of both prototypes under a compound that can be used subsequently as a
mixture with surfactant. With regard to the MMAD values, the results with both prototypes showed
relatively uniform values, close to 12 µm, for the two driving pressures considered. The largest value
(13.08± 0.36 µm) was obtained with PFD and prototype 1 applying a driving pressure of 3 bar whereas
prototype 2 with FC75 provided a minimum value of 11.96 ± 0.17 µm (see Figure 5a). The large
difference in the MMAD results obtained, compared with those under distilled water, may be caused
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due to the high volatility of the PFCs compounds. The Da in all the cases tested was below 5 µm,
as represented in Figure 5b. The results with prototype 2 were slightly lower than those with prototype
1 for each case and driving pressure. In addition, larger values were achieved with PFD irrespective
of the prototype geometry and the pressure defined. The two half-circular rings surrounding the
prototype 2, where the air is delivered, instead of the circular lumens of prototype 1 may contribute to
a larger breakup of the PFCs and, therefore, the generation of smaller droplets. The largest value was
achieved with prototype 1 and PFD (5.00 ± 1.38 µm) whereas prototype 2 with FC75 provided the
minimum value (2.87 ± 0.07 µm). In addition, for the same pressure and the same prototype, the size
of the droplets is smaller for the case with FC75 in comparison with PFD, as shown in Figure 5b.
The reason could be found in the fact that the vapor pressure of the FC75 (63 mmHg) is four times
larger than the PFD (14 mmHg). In the case of FC75, the nebulization might lead to the development
of smaller droplets or even the generation of PFC vapor [31,45].
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Table 3. Geometric standard deviation (GSD) for both prototypes nebulizing PFD and FC75 at
different pressures.
PROTOTYPE 1 (a) PROTOTYPE 2 (a)
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(a) Values are given as ean ± standard deviation.
4. Discussion
The potential advantages of minimally invasive techniques in the treatment of different respiratory
diseases has emerged the study of alternative methods as the aerosolization. The current experimental
study was carried out to evaluate and compare two novel nebulizer prototypes to generate respirable
droplets with potential to be delivered in the supraglottic region. The prototypes were created by
additive manufacturing techniques and subsequently tested with an APS in order to measure the
particle size distribution.
This study reflects the i portance of the nebulizers’ geometry and how it can affect in the aerosol
size distribution. A main finding of the evaluation of these two novel nebulizer prototypes was
that they produced droplets with aerodynamic diameters within the optimal range recommended
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of Da = 1–5 µm for its correct inhalation [46]. In the upper respiratory tract, droplets of 2–5 µm are
desirable. Particles of size larger than 5 µm are mainly deposited by impaction in the oropharyngeal
region and are unable to reach to the lungs, whereas particles of size smaller than 1 µm are mostly
exhaled without deposition. It is also important to note that the MMAD values obtained were between
6–13 µm and, therefore, a high amount of the aerosol is transported by droplets larger than 5 µm.
Nevertheless, a larger MMAD values might not be a problem taking into account that the aim of
these prototypes is to be placed in the supraglottic region. Due to the spreading properties of viscous
substances as the surfactant, droplets with larger diameters than 5 µm could reach the lungs along
with finer particles that could penetrate further into the smaller airways for deep lung delivery [36].
With regard to prototype 1, our findings with distilled water showed similar values in terms of Da
compared with those obtained by Goikoetxea et al. [33] using the Aeroprobe pneumatic catheter.
In addition, PFCs provided slightly larger Da values with both prototypes. In this study, the Da value
varies in a range of 3–5 µm while in Goikoetxea et al. [33] values approximately of 2 µm were measured.
This increment could be benefit to obtain a better deep lung deposition. The difference in MMAD
with PFCs between both studies is more pronounced, since the prototypes presented in the current
study provided most of the aerosol mass distributed in droplets within 10–20 µm. The results with
the Aeroprobe pneumatic catheter showed lower MMAD values even though the experiments were
also carried out at higher driving pressures (4–7 bar). On the other hand, an important difference in
particle size distribution was observed with the atomizing system of Milesi et al. [37], where droplets
with median diameter of 40–60 µm were measured at the tip of their catheter tip.
Figure A1 of the Appendix A represents the particle mass and number distribution of one of
the aerosol samples taken for distilled water with each prototype and the same driving pressure.
From there, it can be visualized how the particle mass concentration with prototype 1 is transported
by droplets in a wider range than prototype 2, where most of the aerosol mass is formed by droplets of
10–20 µm. However, taking into account the concentration number, prototype 2 presents most of the
droplets classified below 3 µm, which is in concordance with the difference between the values of Da
and MMAD explained in the results. The different behavior of prototype 2 with respect to prototype
1 may be attributed to the half-circular ring geometry proposed for the air delivery and its possible
influence in the breakup and coalescence of the aerosol droplets.
The study presents some limitations that must be acknowledged. During the particle size
distribution measurements it was observed that the aerosolization rate was too high to nebulize
the 5 mL of compound contained in the liquid chamber in each sample. This issue is directly related
with the dimensions of the nebulizer lumens of the prototypes manufactured, which were adjusted as
close as possible to the limitations of the 3D printer. The dimensions of the lumens in the distal tip of
the prototypes are being currently adjusted for subsequent studies in order to produce an aerosol with
lower aerosolization rates, i.e., an increase in the aerosolization time to administer a dose. This will
also lead to a reduction in the distal pressure, which is indispensable not to exceed a value of 10 cm
H2O suggested by neonatologists. All these aspects should be addressed in the development of new
improved prototypes and in future experimental studies.
5. Conclusions
The constant investigation of new minimally invasive techniques to treat the respiratory distress
syndrome has lead to the research of alternative approaches as the aerosolization. Since clinical studies
to date have shown discrepancies in the results, different research lines are under study to evaluate
new aerosol devices, their placement within the respiratory system and variations in the compound
preparations and doses. In the present work, the aerosol generation of two novel nebulizer prototypes,
with different distal geometries, has been evaluated with distilled water and two PFCs.
Overall, the current study demonstrates the feasibility of these novel jet nebulizers to produce an
aerosol and generate droplets of respirable size. However, differences have been observed between the
two different geometries proposed. Prototype 1 produces a wider mass distribution than prototype
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2, which provides most of the particle mass distribution in droplets between 10–20 µm, even though
there is an increment in the number of smaller droplets with respect to prototype 1. Consequently,
distal shapes with outer lumens similar to prototype 1 seem to be more suitable for the generation and
delivery of a uniform aerosol than prototype 2.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/1/19/s1,
Figure S1: Representation of the nebulizer prototype 2; Figure S2: Nebulization example with prototype 2;
Figure S3: Experimental setup placed in the laboratory for the nebulization with both prototypes; Figure S4:
(a) Setup of the nebulizer with the liquid chamber where the liquid is supplied and (b) detail of the connections to
administer the compressed air and the liquid respectively.
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Figure A1. Mass and number distribution of an H2Od aerosol sample with prototype 1 (left) and 
prototype 2 (right). (Screenshots taken directly from the Aerosol Instrument Manager software). 
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